Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 83.98Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 83.98Mです。
割安
同社の最新のPEは-7.66で、過去3年間の水準と比較して安値圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は121.98M株で、前四半期比で17.09%増加しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は2.18です。